Who makes HSK39297 300mgQD?

HSK39297 300mgQD is developed by Haisco Pharmaceutical Group Co., Ltd..

What development phase is HSK39297 300mgQD in?

HSK39297 300mgQD is in Phase 2.

Last reviewed 2026-04-19 · How we verify

HSK39297 300mgQD

Haisco Pharmaceutical Group Co., Ltd. · Phase 2 active Small molecule

At a glance

Generic name	HSK39297 300mgQD
Sponsor	Haisco Pharmaceutical Group Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HSK39297 300mgQD CI brief — competitive landscape report
HSK39297 300mgQD updates RSS · CI watch RSS
Haisco Pharmaceutical Group Co., Ltd. portfolio CI